Compare Neurocrine Biosciences Inc (NBIX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nomura Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.4% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nomura Holdings Inc for 55 Days on average.
| NBIX | NMR | |
|---|---|---|
Market Cap | $14.36B | $27.55B |
Volume | 1,237,180 | 782,470 |
Sector | Health | Financials |
52-Week High | $185.50 | $10.86 |
52-Week Low | $123.10 | $6.73 |
Typical Hold Time | 23 Days | 55 Days |
Enterprise Value | $14.37B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Nomura Holdings (NMR) trades at $9.57, showing modest daily gains of 0.42%. The stock presents a mixed technical picture with bearish moving averages but oversold RSI readings. Fundamentally, NMR demonstrates strong profitability with 20.4% net margins and attractive valuation metrics including a P/E of 11.33 and P/B of 1.15. Recent earnings show volatility with two misses and one beat in the last four quarters. The company maintains robust revenue growth, reaching $1.66 trillion in 2025 with expanding profit margins.
NMR offers value investment appeal with reasonable valuations and solid profitability, though technical weakness and inconsistent earnings performance present near-term challenges. The stock's current oversold condition combined with strong fundamental metrics suggests potential for recovery, but investors should monitor earnings consistency and debt levels that have been trending upward. Analyst sentiment remains cautiously optimistic with a buy rating consensus despite recent technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
